Several factors contribute to it: High research and development costs: These medications required years of research, clinical trials, and safety testing, which collectively cost manufacturers billions of dollars before they were approved
Conjunctivitis, Keratitis, and Blepharitis: Conjunctivitis and keratitis occurred more frequently in AD, COPD, and BP subjects who received DUPIXENT versus placebo, with conjunctivitis being the most frequently reported eye disorder in AD
Saxenda oder Nevolat Spritzen (Wirkstoff Liraglutid): Beide Arzneimittel zhlen ebenso wie Wegovy zu den GLP-1-Agonisten und sollen das Hungergefhl regulieren
All of this is attainable with the tools we have today
Not quite: The Wegovy pill produced about 14% average weight loss in trials, while injectable Wegovy can see an average weight loss af about 18.7%